ALNY is expected to report earnings to fall 3.80% to $1.77 per share on October 29
Q3'26
Est.
$1.77
Q2'26
Beat
by $0.24
Q1'26
Beat
by $1.08
Q4'25
Beat
by $0.06
Q3'25
Beat
by $2.38
The last earnings report on July 30 showed earnings per share of $1.84, beating the estimate of $1.60. With 708.53K shares outstanding, the current market capitalization sits at 35.78B.
A.I. Advisor
published General Information
General Information
a developer of therapeutics based on RNA interference
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with PHAT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then PHAT could also see price increases.
ALNY in +11.10% Uptrend, rising for three consecutive days on September 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALNY advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on ALNY as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALNY just turned positive on August 14, 2026. Looking at past instances where ALNY's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
ALNY moved above its 50-day moving average on September 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALNY broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALNY entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.455) is normal, around the industry mean (20.583). P/E Ratio (46.585) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.345) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (7.722) is also within normal values, averaging (443.835).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
